VivoSeq
Ophthalmology

Fuchs Endothelial Corneal Dystrophy

4

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Fuchs endothelial corneal dystrophy is an early-stage landscape with 4 programs across 2 companies. The most active players are Design Therapeutics, Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Design Therapeutics, Inc.

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Unknown status1 · 14%
Recruiting1 · 14%
Enrolling by invitation1 · 14%

Clinical Trials

Trial Activity

7 trials

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Recruiting·DDesign Therapeutics, Inc.·Phase 2·NCT07024693·28 enrolled
The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy
Enrolling by invitation·UUniversity Hospital Dubrava·N/A·NCT06969586·50 enrolled
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
Completed·SSanten Inc.·Phase 2·NCT05376176·86 enrolled
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Completed·KKowa Research Institute, Inc.·Phase 2·NCT04250207·65 enrolled
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Completed·KKowa Research Institute, Inc.·Phase 3·NCT05795699·107 enrolled
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Completed·KKowa Research Institute, Inc.·Phase 3·NCT05826353·110 enrolled
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
Unknown status·UUniversity of Erlangen-Nürnberg Medical School·Phase 2·NCT03575130·21 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)